Lassen is developing novel antibodies with the goal of creating transformational medicines.

Our lead program is a first-in-class and best-in-class monoclonal antibody to block the IL-11 pathway.

IL-11 is a novel target with a central role in fibrotic signaling, different from other factors such as TGF-β, CTGF, and IL-13. Inhibition of IL-11 represents an alternative to targeting signal transducing kinases and intracellular transcription factors and has applications in high unmet needs including fibrosis and oncology.

Lassen Therapeutics pipeline. LAS- N01 in preclinical, one additional undisclosed target in discovery